Business Wire

OBILET

4.8.2021 11:02:07 CEST | Business Wire | Press release

Share
European Online Travel Champion obilet.com Ready for Record Growth

obilet.com, Turkey’s premier online travel ticketing platform, is set to enjoy rapid growth in the wake of the Covid-19 pandemic. Having just acquired its arch-rival Biletall, Obilet is forecast to sell more than 20 million tickets in 2021 – up from 8 million in 2020 – and close out the year with $300 million GMV.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210804005055/en/

Thanks to its unique offerings and innovative business model, the Istanbul-based travel-tech firm is now poised to expand its geographic reach amid an expected post-Covid global recovery.

SaaS-Powered Business Model

Already known throughout the region for its enormously popular ticket-booking app, Obilet’s primary distinction lies in its SaaS (Software-as-a-Service) powered business model. Obilet, invested in by EarlyBird and EBRD, provides bus operators with a best-in-class Ticket Management System (TMS) featuring 24/7 technical support. The company thereby creates a “lock-in effect” for its business operations on the supply side.

By distributing its portfolio of bus operators using its SaaS to other online ticketing platforms on a revenue-sharing basis, Obilet adds additional revenue streams on top of its lucrative B2C sales.

One of the world’s top-10 platforms for online bus and flight tickets, obilet.com saw remarkable growth in the pre-Covid-19 2016-2019 period, boasting a compound annual growth rate (CAGR) of 77%.

Biletall Buyout Cements Leading Position

Earlier last month (July 12), Obilet cemented its regional position by acquiring Biletall, its chief B2C and B2B competitor, which since the 2000s had played a pioneering role in the digitalization of Turkey’s travel industry. Although Obilet stole the top spot from Biletall in 2016 on the B2C side, Biletall nevertheless retained its leading position at B2B coverage.

The acquisition will give Obilet 100% destination coverage in one of the world’s largest bus markets, and the biggest in Europe. Turkey’s intra-state bus market currently generates some 200 million ticket sales per year, corresponding to roughly $3 billion annually.

Currently, more than 300 bus operators compete in this highly fragmented market, which remains largely unconsolidated despite the 2019 acquisition of the country’s largest domestic bus operator by Flix.

Plans for Expansion in Post-Covid Era

Obilet now is equipped with plug-and-play B2B and SaaS solutions to be offered to both operators and online/offline ticket resellers in neighboring countries, where there is huge revenue potential for the Turkish start-up.

Obilet’s vastly enhanced market share, coupled with rising travel demand in the post-Covid era, is expected to yield 40 million ticket sales in 2022 and a GMV of over $500 million. Company officials even suggest that, as Obilet gradually expands into fresh markets, annual GMV could reach as much as $1 billion within the next few years.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release

Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me

BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release

Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release

Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely

MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release

The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav

New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release

Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye